NCT06617013NARecruiting

GERD in Children With Cystic Fibrosis

Duke University

Start Date

10/23/2024

Completion Date

6/30/2026

Summary

The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.

Eligibility Criteria

Age Range: 2 years to 18 years

Inclusion Criteria: * Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations. * Signed consent Exclusion Criteria: * Declining to participate in the study or sign consent * History of severe GERD per gastroenterology diagnosis and documentation * GSAS score \>80

Interventions

OTHER

Discontinuation of GERD therapy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

GERD in ChildrenCystic Fibrosis in Children

Locations

Duke University Hospital

Durham, North Carolina 27710

United States